APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer

Docetaxel is the chemotherapeutic choice for metastatic hormone-refractory prostate cancer, however, it only marginally improves the survival rate. The purpose of the present study was to examine if a peptide targeting the cellular scaffold protein PCNA could improve docetaxel’s efficacy. We found t...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Søgaard, Caroline K., Moestue, Siver A., Rye, Morten B., Kim, Jana, Nepal, Anala, Liabakk, Nina-Beate, Bachke, Siri, Bathen, Tone F., Otterlei, Marit, Hill, Deborah K.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2018
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837745/
https://ncbi.nlm.nih.gov/pubmed/29545934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24357
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items